First group of healthy volunteers dosed in QRL-101 MAD study - ALS News Today
Quralis completes dosing in Phase 1 trial of QRL-101, an oral small molecule for ALS, with 60 volunteers divided into five groups. QRL-101 targets Kv7.2/7.3 channels to reduce motor neuron hyperexcitability, with results expected in early 2025.
Related Clinical Trials
Reference News
First group of healthy volunteers dosed in QRL-101 MAD study - ALS News Today
Quralis completes dosing in Phase 1 trial of QRL-101, an oral small molecule for ALS, with 60 volunteers divided into five groups. QRL-101 targets Kv7.2/7.3 channels to reduce motor neuron hyperexcitability, with results expected in early 2025.